jurkat clone e6 1 cells Search Results


jurkat, clone e6-1  (ATCC)
99
ATCC jurkat, clone e6-1
Jurkat, Clone E6 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jurkat, clone e6-1/product/ATCC
Average 99 stars, based on 1 article reviews
jurkat, clone e6-1 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
human acute t lymphoblastic leukemia jurkat clone e6-1 cells  (Korean Cell Line Bank)
90
Korean Cell Line Bank human acute t lymphoblastic leukemia jurkat clone e6-1 cells
Human Acute T Lymphoblastic Leukemia Jurkat Clone E6 1 Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human acute t lymphoblastic leukemia jurkat clone e6-1 cells/product/Korean Cell Line Bank
Average 90 stars, based on 1 article reviews
human acute t lymphoblastic leukemia jurkat clone e6-1 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
jurkat cell line (clone e6-1)  (Uman Diagnostics)
90
Uman Diagnostics jurkat cell line (clone e6-1)
Jurkat Cell Line (Clone E6 1), supplied by Uman Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jurkat cell line (clone e6-1)/product/Uman Diagnostics
Average 90 stars, based on 1 article reviews
jurkat cell line (clone e6-1) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
jurkat (clone e6–1) cells  (Purdue University Cytometry)
90
Purdue University Cytometry jurkat (clone e6–1) cells
(A) Survival analysis of BALB/c mice bearing pulmonary 4T07 tumors following treatment with the indicated therapies (n=5 mice per group). The combination group of mice received both FIIN4 (100mg/kg/day for 14 days via oral gavage) and anti-PD-L1 (four doses of 200 μg once every three days via intraperitoneal injections) simultaneously. The 14-day FIIN4 treatment is indicated by the solid black line and each anti-PD-L1 administration is denoted by an arrowhead. (B) 4T07 cells were cocultured in vitro with splenocytes from 4T07 tumor bearing mice in the presence or absence of FIIN4 (100 nM) and tumor cell lysis was quantified as described in the materials and methods. Data are mean of triplicate experiments and data were compared using a paired T-test resulting in the indicated p value. (C) <t>Jurkat</t> T-cells pretreated with either DMSO or 1μM FIIN4 overnight were stimulated with CD3-specific antibody for the indicated time points, and cell lysates were collected and assayed via immunoblot for phosphorylation of p-Lck, p-PLCγ1, p-SLP76, p-ZAP70(Y319), p-LAT, and β-tubulin (β-Tub) as a loading control. Data in panel C are representative of at least two independent experiments. (D) Survival analyses of BALB/c mice bearing pulmonary 4T07 tumors treated with indicated therapies (n=10 mice per group). As in panel A, FIIN4 treatment duration (100 mg/kg/day) is indicated by the solid line and anti-PD-L1 doses (200 μg) are indicated by the arrowheads. Survival data were analyzed by a log rank test. (E) Bioluminescent images of the different treatment groups described in panel D at Day 17 post tail vein injections.
Jurkat (Clone E6–1) Cells, supplied by Purdue University Cytometry, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jurkat (clone e6–1) cells/product/Purdue University Cytometry
Average 90 stars, based on 1 article reviews
jurkat (clone e6–1) cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human jurkat t lymphoma cells (clone e6-1)  (Biochrom)
90
Biochrom human jurkat t lymphoma cells (clone e6-1)
(A) Survival analysis of BALB/c mice bearing pulmonary 4T07 tumors following treatment with the indicated therapies (n=5 mice per group). The combination group of mice received both FIIN4 (100mg/kg/day for 14 days via oral gavage) and anti-PD-L1 (four doses of 200 μg once every three days via intraperitoneal injections) simultaneously. The 14-day FIIN4 treatment is indicated by the solid black line and each anti-PD-L1 administration is denoted by an arrowhead. (B) 4T07 cells were cocultured in vitro with splenocytes from 4T07 tumor bearing mice in the presence or absence of FIIN4 (100 nM) and tumor cell lysis was quantified as described in the materials and methods. Data are mean of triplicate experiments and data were compared using a paired T-test resulting in the indicated p value. (C) <t>Jurkat</t> T-cells pretreated with either DMSO or 1μM FIIN4 overnight were stimulated with CD3-specific antibody for the indicated time points, and cell lysates were collected and assayed via immunoblot for phosphorylation of p-Lck, p-PLCγ1, p-SLP76, p-ZAP70(Y319), p-LAT, and β-tubulin (β-Tub) as a loading control. Data in panel C are representative of at least two independent experiments. (D) Survival analyses of BALB/c mice bearing pulmonary 4T07 tumors treated with indicated therapies (n=10 mice per group). As in panel A, FIIN4 treatment duration (100 mg/kg/day) is indicated by the solid line and anti-PD-L1 doses (200 μg) are indicated by the arrowheads. Survival data were analyzed by a log rank test. (E) Bioluminescent images of the different treatment groups described in panel D at Day 17 post tail vein injections.
Human Jurkat T Lymphoma Cells (Clone E6 1), supplied by Biochrom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human jurkat t lymphoma cells (clone e6-1)/product/Biochrom
Average 90 stars, based on 1 article reviews
human jurkat t lymphoma cells (clone e6-1) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human t lymphoblastoid cell line (jurkat, clone e6-1)  (EuroClone)
90
EuroClone human t lymphoblastoid cell line (jurkat, clone e6-1)
(A) Survival analysis of BALB/c mice bearing pulmonary 4T07 tumors following treatment with the indicated therapies (n=5 mice per group). The combination group of mice received both FIIN4 (100mg/kg/day for 14 days via oral gavage) and anti-PD-L1 (four doses of 200 μg once every three days via intraperitoneal injections) simultaneously. The 14-day FIIN4 treatment is indicated by the solid black line and each anti-PD-L1 administration is denoted by an arrowhead. (B) 4T07 cells were cocultured in vitro with splenocytes from 4T07 tumor bearing mice in the presence or absence of FIIN4 (100 nM) and tumor cell lysis was quantified as described in the materials and methods. Data are mean of triplicate experiments and data were compared using a paired T-test resulting in the indicated p value. (C) <t>Jurkat</t> T-cells pretreated with either DMSO or 1μM FIIN4 overnight were stimulated with CD3-specific antibody for the indicated time points, and cell lysates were collected and assayed via immunoblot for phosphorylation of p-Lck, p-PLCγ1, p-SLP76, p-ZAP70(Y319), p-LAT, and β-tubulin (β-Tub) as a loading control. Data in panel C are representative of at least two independent experiments. (D) Survival analyses of BALB/c mice bearing pulmonary 4T07 tumors treated with indicated therapies (n=10 mice per group). As in panel A, FIIN4 treatment duration (100 mg/kg/day) is indicated by the solid line and anti-PD-L1 doses (200 μg) are indicated by the arrowheads. Survival data were analyzed by a log rank test. (E) Bioluminescent images of the different treatment groups described in panel D at Day 17 post tail vein injections.
Human T Lymphoblastoid Cell Line (Jurkat, Clone E6 1), supplied by EuroClone, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human t lymphoblastoid cell line (jurkat, clone e6-1)/product/EuroClone
Average 90 stars, based on 1 article reviews
human t lymphoblastoid cell line (jurkat, clone e6-1) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
jurkat cell line clone e6–1 bcrc 60424  (BioResource International Inc)
90
BioResource International Inc jurkat cell line clone e6–1 bcrc 60424
(A) Survival analysis of BALB/c mice bearing pulmonary 4T07 tumors following treatment with the indicated therapies (n=5 mice per group). The combination group of mice received both FIIN4 (100mg/kg/day for 14 days via oral gavage) and anti-PD-L1 (four doses of 200 μg once every three days via intraperitoneal injections) simultaneously. The 14-day FIIN4 treatment is indicated by the solid black line and each anti-PD-L1 administration is denoted by an arrowhead. (B) 4T07 cells were cocultured in vitro with splenocytes from 4T07 tumor bearing mice in the presence or absence of FIIN4 (100 nM) and tumor cell lysis was quantified as described in the materials and methods. Data are mean of triplicate experiments and data were compared using a paired T-test resulting in the indicated p value. (C) <t>Jurkat</t> T-cells pretreated with either DMSO or 1μM FIIN4 overnight were stimulated with CD3-specific antibody for the indicated time points, and cell lysates were collected and assayed via immunoblot for phosphorylation of p-Lck, p-PLCγ1, p-SLP76, p-ZAP70(Y319), p-LAT, and β-tubulin (β-Tub) as a loading control. Data in panel C are representative of at least two independent experiments. (D) Survival analyses of BALB/c mice bearing pulmonary 4T07 tumors treated with indicated therapies (n=10 mice per group). As in panel A, FIIN4 treatment duration (100 mg/kg/day) is indicated by the solid line and anti-PD-L1 doses (200 μg) are indicated by the arrowheads. Survival data were analyzed by a log rank test. (E) Bioluminescent images of the different treatment groups described in panel D at Day 17 post tail vein injections.
Jurkat Cell Line Clone E6–1 Bcrc 60424, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jurkat cell line clone e6–1 bcrc 60424/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
jurkat cell line clone e6–1 bcrc 60424 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
jurkat clone e6-1 cell line  (Genentech inc)
90
Genentech inc jurkat clone e6-1 cell line
(A) Survival analysis of BALB/c mice bearing pulmonary 4T07 tumors following treatment with the indicated therapies (n=5 mice per group). The combination group of mice received both FIIN4 (100mg/kg/day for 14 days via oral gavage) and anti-PD-L1 (four doses of 200 μg once every three days via intraperitoneal injections) simultaneously. The 14-day FIIN4 treatment is indicated by the solid black line and each anti-PD-L1 administration is denoted by an arrowhead. (B) 4T07 cells were cocultured in vitro with splenocytes from 4T07 tumor bearing mice in the presence or absence of FIIN4 (100 nM) and tumor cell lysis was quantified as described in the materials and methods. Data are mean of triplicate experiments and data were compared using a paired T-test resulting in the indicated p value. (C) <t>Jurkat</t> T-cells pretreated with either DMSO or 1μM FIIN4 overnight were stimulated with CD3-specific antibody for the indicated time points, and cell lysates were collected and assayed via immunoblot for phosphorylation of p-Lck, p-PLCγ1, p-SLP76, p-ZAP70(Y319), p-LAT, and β-tubulin (β-Tub) as a loading control. Data in panel C are representative of at least two independent experiments. (D) Survival analyses of BALB/c mice bearing pulmonary 4T07 tumors treated with indicated therapies (n=10 mice per group). As in panel A, FIIN4 treatment duration (100 mg/kg/day) is indicated by the solid line and anti-PD-L1 doses (200 μg) are indicated by the arrowheads. Survival data were analyzed by a log rank test. (E) Bioluminescent images of the different treatment groups described in panel D at Day 17 post tail vein injections.
Jurkat Clone E6 1 Cell Line, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jurkat clone e6-1 cell line/product/Genentech inc
Average 90 stars, based on 1 article reviews
jurkat clone e6-1 cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
jurkat cells clone e6-1  (BioResource International Inc)
90
BioResource International Inc jurkat cells clone e6-1
(A) Survival analysis of BALB/c mice bearing pulmonary 4T07 tumors following treatment with the indicated therapies (n=5 mice per group). The combination group of mice received both FIIN4 (100mg/kg/day for 14 days via oral gavage) and anti-PD-L1 (four doses of 200 μg once every three days via intraperitoneal injections) simultaneously. The 14-day FIIN4 treatment is indicated by the solid black line and each anti-PD-L1 administration is denoted by an arrowhead. (B) 4T07 cells were cocultured in vitro with splenocytes from 4T07 tumor bearing mice in the presence or absence of FIIN4 (100 nM) and tumor cell lysis was quantified as described in the materials and methods. Data are mean of triplicate experiments and data were compared using a paired T-test resulting in the indicated p value. (C) <t>Jurkat</t> T-cells pretreated with either DMSO or 1μM FIIN4 overnight were stimulated with CD3-specific antibody for the indicated time points, and cell lysates were collected and assayed via immunoblot for phosphorylation of p-Lck, p-PLCγ1, p-SLP76, p-ZAP70(Y319), p-LAT, and β-tubulin (β-Tub) as a loading control. Data in panel C are representative of at least two independent experiments. (D) Survival analyses of BALB/c mice bearing pulmonary 4T07 tumors treated with indicated therapies (n=10 mice per group). As in panel A, FIIN4 treatment duration (100 mg/kg/day) is indicated by the solid line and anti-PD-L1 doses (200 μg) are indicated by the arrowheads. Survival data were analyzed by a log rank test. (E) Bioluminescent images of the different treatment groups described in panel D at Day 17 post tail vein injections.
Jurkat Cells Clone E6 1, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jurkat cells clone e6-1/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
jurkat cells clone e6-1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) Survival analysis of BALB/c mice bearing pulmonary 4T07 tumors following treatment with the indicated therapies (n=5 mice per group). The combination group of mice received both FIIN4 (100mg/kg/day for 14 days via oral gavage) and anti-PD-L1 (four doses of 200 μg once every three days via intraperitoneal injections) simultaneously. The 14-day FIIN4 treatment is indicated by the solid black line and each anti-PD-L1 administration is denoted by an arrowhead. (B) 4T07 cells were cocultured in vitro with splenocytes from 4T07 tumor bearing mice in the presence or absence of FIIN4 (100 nM) and tumor cell lysis was quantified as described in the materials and methods. Data are mean of triplicate experiments and data were compared using a paired T-test resulting in the indicated p value. (C) Jurkat T-cells pretreated with either DMSO or 1μM FIIN4 overnight were stimulated with CD3-specific antibody for the indicated time points, and cell lysates were collected and assayed via immunoblot for phosphorylation of p-Lck, p-PLCγ1, p-SLP76, p-ZAP70(Y319), p-LAT, and β-tubulin (β-Tub) as a loading control. Data in panel C are representative of at least two independent experiments. (D) Survival analyses of BALB/c mice bearing pulmonary 4T07 tumors treated with indicated therapies (n=10 mice per group). As in panel A, FIIN4 treatment duration (100 mg/kg/day) is indicated by the solid line and anti-PD-L1 doses (200 μg) are indicated by the arrowheads. Survival data were analyzed by a log rank test. (E) Bioluminescent images of the different treatment groups described in panel D at Day 17 post tail vein injections.

Journal: Cancer immunology research

Article Title: Pharmacological inhibition of FGFR modulates the metastatic immune microenvironment and promotes response to immune checkpoint blockade

doi: 10.1158/2326-6066.CIR-20-0235

Figure Lengend Snippet: (A) Survival analysis of BALB/c mice bearing pulmonary 4T07 tumors following treatment with the indicated therapies (n=5 mice per group). The combination group of mice received both FIIN4 (100mg/kg/day for 14 days via oral gavage) and anti-PD-L1 (four doses of 200 μg once every three days via intraperitoneal injections) simultaneously. The 14-day FIIN4 treatment is indicated by the solid black line and each anti-PD-L1 administration is denoted by an arrowhead. (B) 4T07 cells were cocultured in vitro with splenocytes from 4T07 tumor bearing mice in the presence or absence of FIIN4 (100 nM) and tumor cell lysis was quantified as described in the materials and methods. Data are mean of triplicate experiments and data were compared using a paired T-test resulting in the indicated p value. (C) Jurkat T-cells pretreated with either DMSO or 1μM FIIN4 overnight were stimulated with CD3-specific antibody for the indicated time points, and cell lysates were collected and assayed via immunoblot for phosphorylation of p-Lck, p-PLCγ1, p-SLP76, p-ZAP70(Y319), p-LAT, and β-tubulin (β-Tub) as a loading control. Data in panel C are representative of at least two independent experiments. (D) Survival analyses of BALB/c mice bearing pulmonary 4T07 tumors treated with indicated therapies (n=10 mice per group). As in panel A, FIIN4 treatment duration (100 mg/kg/day) is indicated by the solid line and anti-PD-L1 doses (200 μg) are indicated by the arrowheads. Survival data were analyzed by a log rank test. (E) Bioluminescent images of the different treatment groups described in panel D at Day 17 post tail vein injections.

Article Snippet: Jurkat (clone e6–1) cells were obtained from Kazemian lab (Purdue University) in 2018.

Techniques: In Vitro, Lysis, Western Blot, Phospho-proteomics, Control